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ORIGINAL RESEARCH
Impact of Plasma Potassium Normalization 
on Short-Term Mortality in Patients With 
Hypertension and Hyperkalemia
Maria Lukács Krogager , MD; Peter Søgaard , MD, DMSc; Christian Torp-Pedersen, MD, DMSc;  
Henrik Bøggild , MD; Gunnar Gislason , MD, DMSc; Kristian Kragholm, MD, PhD
BACKGROUND: Hyperkalemia can be harmful, but the effect of correcting hyperkalemia is sparsely studied. We used nationwide 
data to examine hyperkalemia follow-up in patients with hypertension.
METHODS AND RESULTS: We identified 7620 patients with hypertension, who had the first plasma potassium measurement 
≥4.7 mmol/L (hyperkalemia) within 100 days of combination antihypertensive therapy initiation. A second potassium was 
measured 6 to 100 days after the episode of hyperkalemia. All-cause mortality within 90 days of the second potassium meas-
urement was assessed using Cox regression. Mortality was examined for 8 predefined potassium intervals derived from the 
second measurement: 2.2 to 2.9 mmol/L (n=37), 3.0 to 3.4 mmol/L (n=184), 3.5 to 3.7 mmol/L (n=325), 3.8 to 4.0 mmol/L 
(n=791), 4.1 to 4.6 mmol/L (n=3533, reference), 4.7 to 5.0 mmol/L (n=1786), 5.1 to 5.5 mmol/L (n=720), and 5.6 to 7.8 mmol/L 
(n=244). Ninety-day mortality in the 8 strata was 37.8%, 21.2%, 14.5%, 9.6%, 6.3%, 6.2%, 10.0%, and 16.4%, respectively. 
The multivariable analysis showed that patients with concentrations >5.5 mmol/L after an episode of hyperkalemia had in-
creased mortality risk compared with the reference (hazard ratio [HR], 2.27; 95% CI, 1.60–3.20; P<0.001). Potassium intervals 
3.5 to 3.7 mmol/L and 3.8 to 4.0 mmol/L were also associated with increased risk of death (HR, 1.71; 95% CI, 1.23–2.37; 
P<0.001; HR, 1.36; 95% CI, 1.04–1.76; P<0.001, respectively) compared with the reference group. We observed a trend to-
ward increased risk of death within the interval 5.1 to 5.5 mmol/L (HR, 1.29; 95% CI, 0.98–1.69). Potassium concentrations 
<4.1 mmol/L and >5.0 mmol/L were associated with increased risk of cardiovascular death.
CONCLUSIONS: Overcorrection of hyperkalemia to levels <4.1 mmol/L was frequent and associated with increased all-cause 
and cardiovascular mortality. Potassium concentrations >5.5 mmol/L were also associated with an increased all-cause and 
cardiovascular mortality.
Key Words: hyperkalemia ■ hyperkalemia correction ■ hypertension ■ potassium normalization
Potassium plays a key role in maintaining normal myocardial electrical activity. A shift in potassium balance or persistent potassium disturbances can 
have a negative effect on the heart, regardless of the 
direction.1 Patients with persistent cardiovascular dis-
eases, such as hypertension, are especially exposed 
to potassium disturbances attributable to treatment 
side effects.2
We recently demonstrated a U-shaped relationship 
between potassium and mortality among patients with 
hypertension. Mortality risk was higher even for low 
and high normal potassium ranges, suggesting a more 
strict normal interval of 4.1 to 4.7 mmol/L.3 However, 
there are currently no data on the impact of plasma 
potassium normalization on short-term mortality in pa-
tients with hypertension and hyperkalemia. Therefore, 
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it is important to investigate how correction and even 
overcorrection of hyperkalemia changes short-term 
prognosis in patients with hypertension.
Using Danish national registers, we investigated the 
90-day mortality for patients with hypertension and an 
initial high potassium measurement, according to their 
subsequent plasma potassium concentrations mea-
sured within 6 to 100  days following the episode of 
elevated potassium.
METHODS
Availability of Data and Materials
Because of restrictions related to Danish law and pro-
tecting patient privacy, the combined set of data and 
analyses used in this study can be made available 
only through a trusted third party, Statistics Denmark. 
This state organization holds the data used for this 
study. University-based Danish scientific organizations 
can be authorized to work with data within Statistics 
Denmark and such organization can provide access 
to individual scientists inside and outside of Denmark. 
Data are available upon request to authorized scien-
tists by contacting Statistics Denmark (http://www.dst.
dk/en/OmDS/organ isati on/Telef onbog Org.aspx?konto 
r=13&tlfbo gsort =sektion) or the Danish Data Protection 
Agency (https://www.datat ilsyn et.dk/engli sh/the-danis 
h-data-prote ction -agenc y/conta ct/). More informa-
tion regarding data access is available at https://www.
dst.dk/en/TilSa lg/Forsk nings service. Being register 
based, no institutional review board approval or sub-
ject informed consent is needed. Statistics Denmark 
deidentified each citizen before making the data sets 
available for research.
Databases
Residents in Denmark have a personal, unique, and 
permanent civil registration number that enables link-
age of data from all nationwide administrative registries.
The Danish Civil Registration System was used to 
collect data regarding age and sex.4 From the Danish 
National Patient Registry, we obtained information 
about hospital admission dates, hospital discharge 
dates, discharge diagnoses, dates of procedure, and 
procedure codes.5 Discharge diagnoses are coded ac-
cording to the World Health Organization International 
Classification of Diseases (ICD). From 1994 and on-
wards the Tenth Revision (ICD-10) was in use. The 
Danish National Patient Registry covers information 
from 1978 until the present time.
Information on each resident’s redeemed prescrip-
tion was collected from the Danish National Prescription 
Registry.6 This register includes all dispensed prescrip-
tions from all Danish pharmacies since 1995 based 
on the Anatomical Therapeutic Chemical System. The 
Danish healthcare system is state financed and partly 
reimburses drug costs. For this reason, all Danish 
pharmacies are compelled by law to register all dis-
pensed drug prescriptions, providing a complete over-
view of all prescriptions.
The electronic registers of laboratory data contain 
blood test results from 3 of the 5 regions in Denmark, 
covering ≈4 058 000 inhabitants. Blood samples orig-
inated from either primary care, outpatient visits, or 
hospitalizations.
Study Population
Hypertension was defined as first-time redemption 
of at least 2 antihypertensive drugs in 2 consecu-
tive quarters, and this definition has been validated 
previously.7 Patients entered the study in the second 
quarter, and this time was referred to as hypertension 
date. Patients entered the study regardless of being 
prescribed antihypertensives as a single pill combina-
tion or as multiple pills. In this study, we define “com-
bination antihypertensive therapy” as redemption of 
minimum 2 antihypertensive drug classes as a single 
pill or as multiple pills. We applied this definition of 
hypertension for 2 reasons. First, the great majority 
of the patients treated for high blood pressure are 
monitored by the general practitioner and are not 
CLINICAL PERSPECTIVE
What Is New?
• In this register study comprising 7620 patients 
with hyperkalemia, we observed that balanc-
ing hyperkalemia to levels between 4.1 and 
5.5 mmol/L was associated with better short-
term prognosis compared with patients with 
concentrations outside the interval.
• Patients treated with combination antihy-
pertensive therapy, who had hyperkalemia 
(≥4.7 mmol/L) at the first potassium measure-
ment within 100 days of treatment initiation had 
increased 90-day mortality risk if potassium lev-
els were higher than 5.0 mmol/L or lower than 
4.1 mmol/L at the second measurement (within 
6–100 days).
• Hyperkalemia is a common side effect of anti-
hypertensive treatment and is associated with 
arrhythmogenesis and increased mortality risk 
in patients with hypertension.
What Are the Clinical Implications?
• This study suggests that correction of hyper-
kalemia to a level in the high end of the normal 
reference interval is associated with improved 
prognosis.
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registered with a hypertension ICD-10 code dur-
ing hospitalization or outpatient clinic visit. Second, 
most of the drugs used for management of hyper-
tension can also be used to treat other cardiovas-
cular diseases. Therefore, a monotherapy approach 
would be less specific. Olesen et al7 demonstrated 
that treatment with 2 classes of antihypertensive 
agents has a positive predictive value of 80% and a 
specificity of 94.7% to identify patients with hyper-
tension. Table  S1 contains Anatomical Therapeutic 
Chemical System codes used to identify patients 
with hypertension. A plasma potassium measure-
ment >4.6 mmol/L (hyperkalemia) within 100 days of 
the date of hypertension was required to be included 
in the study. The first measurement within this time 
frame was retained and referred to as the first potas-
sium measurement. As the aim of the study was to 
investigate the impact of changes in potassium con-
centrations on mortality in patients with hypertension 
and hyperkalemia, we required a subsequent potas-
sium measurement within 6 to 100 days following the 
first potassium measurement. The first measurement 
within this time frame was retained. This plasma po-
tassium measurement was referred to as the second 
potassium measurement and represents the start of 
follow-up in this study. We considered this time frame 
appropriate, as in most of the cases potassium im-
balances are corrected within a few days, regardless 
of the pharmacological or dietary strategies applied. 
Patients <18  years of age were excluded from the 
study. Figure S1 illustrates the population flowchart.
Comorbidities and Medication
Comorbidities and medication that clinically and 
theoretically could be regarded as confounding fac-
tors in relation to studying the association between 
changes in potassium and short-term mortality were 
identified. We considered patients as having a previ-
ous history with a specific comorbidity if the hospital 
discharge diagnosis was registered before the index 
date. The following comorbidities were identified: 
heart failure, chronic obstructive pulmonary disease, 
ischemic heart disease, chronic liver disease, stroke, 
diabetes mellitus, inflammatory bowel disease, and 
malignancy. Moreover, we excluded patients with a 
past history of primary adrenal insufficiency, primary 
hyperaldosteronism, and diabetes insipidus. The 
ICD-10 codes used to identify these comorbidities 
can be seen in Table  S2. The renal function of the 
patients was calculated using the Chronic Kidney 
Disease Epidemiology Collaboration formula8 and 
an estimated glomerular filtration rate <30  mL/min 
per 1.73  m2 was used to define renal dysfunction. 
We registered creatinine measurements available the 
same day as the index date or within a week from the 
index date in case of missing values. Patients were 
excluded if no creatinine concentrations were avail-
able in this time limit. Additionally, patients with miss-
ing sodium measurements the same day as the index 
date were also excluded.
We identified prescriptions dated up to 90 days be-
fore the index date for the following drugs: laxatives, 
xantines, nonsteroidal anti-inflammatory drugs, corti-
coids, potassium supplement, and antimicrobials. See 
Table S2 for relevant Anatomical Therapeutic Chemical 
System codes.
Exposure Variable
Normal plasma potassium interval varies within popu-
lations. Therefore, different reference intervals are used 
worldwide.9–11 The Nordic Reference Interval Project 
defines hypokalemia as plasma potassium concentra-
tions <3.5  mmol/L and hyperkalemia and potassium 
levels >4.6 mmol/L.10
As potassium does not have a linear relationship 
with mortality, the second potassium measurement 
was divided into 8 intervals: 2.2 to 2.9 mmol/L, 3.0 to 
3.4 mmol/L, 3.5 to 3.7 mmol/L, 3.8 to 4.0 mmol/L, 4.1 
to 4.6 mmol/L, 4.7 to 5.0 mmol/L, 5.1 to 5.5 mmol/L, 
and 5.6 to 7.8 mmol/L. Plasma potassium interval 4.1 
to 4.6 mmol/L was used as the reference for statisti-
cal analyses. We chose this interval as the reference 
group on the basis of the study of Krogager et al3 and 
the lowest mortality risk observed in a restricted cubic 
spline curve (Figure 1).
Outcome
The primary outcome of the study was all-cause mortality 
within 90 days of the second plasma potassium meas-
urement occurring 6 to 100 days after the first plasma 
potassium measurement indicating hyperkalemia. The 
secondary outcome was cardiovascular death within 
90 days of the second potassium measurement.
Statistical Analysis
Categorical variables were presented as counts 
and percentages, and continuous variables as me-
dian and 25th and 75th percentiles. To evaluate dif-
ferences for nonnormally distributed continuous 
variables we used the Kruskal–Wallis test, and for 
differences across categorical variables, we used the 
chi-squared test.
To illustrate survival, Kaplan–Meier curves were 
plotted for the 8 potassium intervals. The Cox propor-
tional regression model was used to investigate the 
association between the 8 potassium groups and mor-
tality. The multivariable model was adjusted for age, 
sex, plasma sodium, renal insufficiency, malignancy, 
heart failure, chronic liver disease, chronic obstructive 
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pulmonary disease, diabetes mellitus, stroke, atrial 
flutter/fibrillation, ischemic heart disease, antihyper-
tensive therapy, corticosteroids, antimicrobials, non-
steroidal anti-inflammatory drugs, xanthines, laxatives, 
digoxin, and potassium supplements. Hazard ratios 
(HRs) were estimated with 95% CIs.
To test the robustness of the main results, 9 sensi-
tivity analyses were constructed: (1) subgroup of pa-
tients with normal kidney function; (2) patients without 
past history of any malignancy; (3) patients without past 
history of heart failure or loop diuretic prescriptions; (4) 
patients without past history of ischemic heart disease; 
(5) patients with available ICD-10 hypertension diag-
nosis; (6) analyses investigating risk of cardiovascular 
death in relation to the 8 potassium intervals; (7) analy-
ses using last instead of first available potassium con-
centrations within 6 to 100 days of first measurement; 
(8) multivariable model adjusted for the first potassium 
measurement; and (9) multivariable model adjusted for 
time between first and second potassium measure-
ment. In the survival analyses, P<0.05 was consid-
ered statistically significant. All data management and 
analyses were performed using SAS, version 9.4 (SAS 
Institute, Cary, NC) and R, version 3.5.0 (R Foundation 
for Statistical Computing, Vienna, Austria).12
RESULTS
Model Construction
The assumption of proportional hazards was tested 
using Schoenfeld residuals, log-minus-log plots and 
log-rank tests. The proportionality assumption was 
not violated in any of the tests above. The follow-
ing variables were tested for interaction with plasma 
potassium on mortality: age, sex, diabetes mellitus, 
and renal dysfunction. A likelihood ratio test compar-
ing the model with and without the interaction term 
was performed. A P value <0.01 was considered as 
a statistically significant interaction. We observed no 
interaction between potassium and age, sex, diabe-
tes mellitus, or renal dysfunction on mortality. The 
same approach was used to assess whether age 
had a linear relationship on mortality. As the linearity 
assumption was not fulfilled for age as a continuous 
variable, age was included in the regression models 
as a categorical variable with 5 levels, using cutoff 
values from 20th percentiles: 18 to 58, 59 to 67, 68 to 
73, 74 to 81, and 82 to 102.
To examine model fit and performance, we cal-
culated the Akaike Information Criterion and the area 
under the receiver operating characteristic curve 
(Table S3).
Demographics
A total of 7620 patients were included in the study 
in the period 1995 to 2017, and the characteristics 
stratified according to the second potassium meas-
urement are shown in Table 1. Median time from first 
to second potassium measurement was 24  days 
(range, 6–100). Of the total population with hyper-
kalemia at the first potassium measurement, 61.01% 
of the patients had normokalemia at the second 
Figure 1. Restricted cubic spline curve showing the adjusted hazard ratios for all-cause mortality 
as a function of second plasma potassium measurement.
Knots at the 25th, 50th, and 75th percentiles of plasma potassium. The model is adjusted for age, sex, 
plasma sodium, renal insufficiency, malignancy, heart failure, chronic liver disease, chronic obstructive 
pulmonary disease, diabetes mellitus, stroke, atrial flutter/fibrillation, ischemic heart disease, inflammatory 
bowel disease, antihypertensive therapy, corticosteroids, antimicrobials, nonsteroidal anti-inflammatory 
drugs, xanthines, laxatives, digoxin, and potassium supplements.
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potassium measurement. We observed that 36.1% 
of the patients with hyperkalemia at the first potas-
sium measurement had elevated potassium concen-
trations at the second measurement as well. Of the 
total patients, 2.9% were overcorrected to hypoka-
lemia. As for patients with potassium levels 4.7 to 
5.5  mmol/L at the first measurement, 3.4% devel-
oped higher (5.6–7.8 mmol/L) concentrations at the 
second measurement. Overall, 39% of the patients 
with hyperkalemia at the first potassium measure-
ment had abnormal concentrations at the second 
measurement. The majority of the patients (84.7%) 
had their second potassium draw taken during hos-
pitalization, and nearly 15% had an estimated glo-
merular filtration rate <30 mL/min per 1.73 m2. Of the 
primary diagnoses assessed at each hospitalization, 
9.7% were related to heart disease and 4.9% attrib-
utable to kidney disease (Table S4).
See Figure  S2 displaying the distribution of the 
first potassium measurement, average of potas-
sium measurements drawn within 1 to 5  days of 
the first potassium measurement (n=2161), and 
second potassium measurement. Of the patients 
with available potassium measurements within 1 
to 5 days of the first potassium measurement indi-
cating hyperkalemia, 7.4% developed hypokalemia, 
and 27.9% persisted with hyperkalemia. Of the 2161 
patients, 1429 had normokalemia at the last potas-
sium measurement within 1 to 5 days from the first 
potassium measurement. Of the 1429 patients who 
achieved normokalemia within 1 to 5  days of hy-
perkalemia, 1043 (81.1%) had persistent normoka-
lemia at the first measurement within 6 to 100 days 
from hyperkalemia (otherwise known as “second 
potassium measurement”). Of the deceased within 
90 days from the second potassium measurement, 
374 (60.1%) had available potassium measurements 
within 1 to 5 days of the first potassium measure-
ment (Table S5).
Predominant comorbidities were ischemic heart 
disease, heart failure, and diabetes mellitus.
Survival Analysis
During 90 days’ follow-up after the second plasma 
potassium measurement, 633 (8.3 %) patients 
died, of which 318 had an underlying cardiovascu-
lar cause. The absolute mortality proportion in the 8 
strata was 37.8%, 21.2%, 14.5%, 9.6%, 6.3%, 6.2%, 
10.0%, and 16.4%, respectively. Survival curves 
are illustrated in Figure 2, and causes of death are 
shown in Table  S6. Patients who died were older, 
with higher kidney insufficiency burden at the time of 
potassium measurement, higher hospitalization rate 
at the time of potassium measurement, and more 
likely with a previous history of malignancy, stroke, 
chronic obstructive pulmonary disease, atrial fibrilla-
tion, and chronic liver disease within the past 5 years 
(Table S7).
The results of the univariable and multivariable 
Cox proportional regression, with plasma potassium 
4.1 to 4.6 mmol/L as the reference group, are shown 
in Figure 3. The univariable analysis showed that po-
tassium concentrations outside the interval 4.1 to 
5.0 mmol/L were associated with increased all-cause 
mortality, in patients with hypertension and initial hy-
perkalemia. Highest mortality was observed in patients 
with potassium levels 2.2 to 2.9  mmol/L (HR, 7.18; 
95% CI, 4.18–12.32; P<0.001), 3.0 to 3.4 mmol/L (HR, 
3.61; 95% CI, 2.57–5.08; P<0.001), 3.5 to 3.7 mmol/L 
(HR, 2.41; 95% CI, 1.76–3.30; P<0.001), and 5.6 to 
7.8  mmol/L (HR, 2.77; 95% CI, 1.98–3.88; P<0.001). 
The multivariable analysis showed similar results, but 
the interval 5.1 to 5.5 mmol/L was no longer associ-
ated with increased mortality (HR, 1.29; 95% CI, 0.98–
1.69; P=0.073).
Sensitivity Analyses
We performed 9 sensitivity analyses to test the robust-
ness of our main results. The findings are shown in 
Table 2.
First, a subgroup analysis on patients with normal 
kidney function was performed (n=6505). The results 
were similar with the main analysis.
Second, a subgroup analysis on patients without 
past history of malignancy (n=6383) also showed sim-
ilar results with the main analysis.
Third, we performed a subgroup analysis on 
population without heart failure or loop diuretic pre-
scription (n=3149). Plasma potassium intervals 2.2 to 
2.9 mmol/L and 3.0 to 3.4 mmol/L were associated 
with increased all-cause mortality (HR, 7.79; 95% CI, 
2.54–23.90; P<0.001; and HR, 2.79; 95% CI, 1.35–
5.78; P=0.006, respectively) compared with the ref-
erence. We also noted a trend toward increased risk 
of death in patients with potassium concentrations 
above 5.5  mmol/L (HR, 1.88; 95% CI, 0.90–3.91; 
P=0.091).
Fourth, we performed an analysis where patients 
with a past history of ischemic heart disease were ex-
cluded (n=5121). The results were similar to the main 
analysis, except lack of statistically significant associa-
tion between potassium interval 3.8 to 4.0 mmol/L and 
90-day mortality.
Fifth, we analyzed only patients with available ICD-
10 hypertension diagnosis (n=2410). The results were 
similar to the main analysis.
Sixth, we analyzed the risk of 90-day cardiovascular 
death with all-cause mortality as competing risk. We 
observed that potassium concentrations outside the in-
terval 4.1 to 5.0 mmol/L were associated with increased 
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risk of cardiovascular mortality after an episode of hy-
perkalemia (2.2–2.9 mmol/L: HR, 6.86; 95% CI, 3.40–
13.85; P<0.001; 3.0–3.4  mmol/L: HR, 3.21; 95% CI, 
2.05–5.04; P<0.001; 3.5–3.7  mmol/L: HR, 1.85; 95% 
CI, 1.15–2.96; P=0.010; 3.8–4.0 mmol/L: HR, 1.56; 95% 
CI, 1.09–2.25; P=0.022; 5.1–5.5 mmol/L: HR, 1.80; 95% 
Figure 2. Kaplan–Meier survival curves across the 8 plasma potassium intervals.
The P values indicate the difference among plasma potassium groups compared with the reference group 
based on log-rank test.
Figure 3. All-cause mortality after hyperkalemia according to subsequent potassium measurements in patients treated 
with combination antihypertensive therapy (90 days’ follow-up, n=7620).
Potassium interval K: 4.1 to 4.6 mmol/L represented the reference range. Adjusted for age, sex, plasma sodium, renal insufficiency, 
malignancy, heart failure, chronic liver disease, chronic obstructive pulmonary disease, diabetes mellitus, stroke, atrial flutter/
fibrillation, ischemic heart disease, antihypertensive therapy, corticosteroids, antimicrobials, nonsteroidal anti-inflammatory drugs, 
xanthines, laxatives, digoxin, and potassium supplements. HR indicates hazard ratio.
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Table 2. Sensitivity Analyses
Univariable Analysis Multivariable Analysis
HR 95% CI P Value HR 95% CI P Value
1. Patients with normal kidney function (N=6505)
2.2–2.9 mmol/L 6.55 (3.35–12.78) <0.001 5.36 (2.71–10.62) <0.001
3.0–3.4 mmol/L 4.17 (2.87–6.08) <0.001 2.90 (1.98–4.25) <0.001
3.5–3.7 mmol/L 2.63 (1.87–3.70) <0.001 1.81 (1.27–2.59) 0.001
3.8–4.0 mmol/L 1.52 (1.14–2.03) 0.005 1.39 (1.04–1.87) 0.03
4.1–4.6 mmol/L REF.
4.7–5.0 mmol/L 0.90 (0.69–1.17) 0.421 0.87 (0.66–1.13) 0.293
5.1–5.5 mmol/L 1.58 (1.15–2.17) 0.005 1.28 (0.93–1.76) 0.132
5.6–7.8 mmol/L 3.43 (2.28–5.17) <0.001 2.73 (1.80–4.14) <0.001
2. Patients without past history of malignancy (N=6383)
2.2–2.9 mmol/L 7.15 (3.51–14.57) <0.001 4.21 (2.00–8.86) <0.001
3.0–3.4 mmol/L 4.15 (2.73–6.30) <0.001 2.91 (1.90–4.44) <0.001
3.5–3.7 mmol/L 2.47 (1.67–3.67) <0.001 1.89 (1.27–2.82) 0.002
3.8–4.0 mmol/L 1.57 (1.13–2.17) 0.007 1.40 (1.02–1.93) 0.039
4.1–4.6 mmol/L REF.
4.7–5.0 mmol/L 1.00 (0.75–1.32) 0.991 0.92 (0.69–1.23) 0.591
5.1–5.5 mmol/L 1.51 (1.07–2.13) 0.021 1.16 (0.81–1.64) 0.443
5.6–7.8 mmol/L 3.01 (2.01–4.52) <0.001 2.35 (1.54–3.57) <0.001
3. Patients without past history of heart failure or loop diuretic prescriptions (N=3149)
2.2–2.9 mmol/L 11.31 (4.55–28.13) <0.001 7.79 (2.54–23.90) <0.001
3.0–3.4 mmol/L 3.80 (1.89–7.64) <0.001 2.79 (1.35–5.78) 0.006
3.5–3.7 mmol/L 1.75 (0.84–3.66) 0.135 1.54 (0.72–3.28) 0.279
3.8–4.0 mmol/L 1.33 (0.79–2.25) 0.282 1.28 (0.75–2.18) 0.374
4.1–4.6 mmol/L REF.
4.7–5.0 mmol/L 0.85 (0.54–1.36) 0.501 0.82 (0.51–1.31) 0.403
5.1–5.5 mmol/L 1.39 (0.82–2.39) 0.224 1.26 (0.73–2.19) 0.418
5.6–7.8 mmol/L 2.58 (1.28–5.18) 0.008 1.88 (0.90–3.91) 0.091
4. Patients without past history of ischemic heart disease (N=5121)
2.2–2.9 mmol/L 8.30 (4.51–15.29) <0.001 6.35 (3.39–11.89) <0.001
3.0–3.4 mmol/L 3.64 (2.49–5.31) <0.001 2.66 (1.80–3.92) <0.001
3.5–3.7 mmol/L 2.87 (2.03–4.06) <0.001 2.53 (1.78–3.60) <0.001
3.8–4.0 mmol/L 1.41 (1.03–1.92) 0.032 1.30 (0.95–1.77) 0.101
4.1–4.6 mmol/L REF.
4.7–5.0 mmol/L 0.91 (0.70–1.19) 0.493 0.87 (0.66–1.14) 0.313
5.1–5.5 mmol/L 1.63 (1.21–2.20) 0.001 1.51 (1.11–2.04) 0.008
5.6–7.8 mmol/L 2.35 (1.56–3.52) <0.001 2.34 (1.55–3.55) <0.001
5. Patients with an ICD-10 hypertension diagnosis (N=2410)
2.2–2.9 mmol/L 10.89 (4.68–25.32) <0.001 5.15 (2.09–12.69) <0.001
3.0–3.4 mmol/L 3.66 (2.00–6.71) <0.001 2.84 (1.52–5.29) 0.001
3.5–3.7 mmol/L 1.53 (0.75–3.09) 0.242 1.04 (0.49–2.18) 0.923
3.8–4.0 mmol/L 1.67 (1.02–2.75) 0.041 1.75 (1.05–2.89) 0.032
4.1–4.6 mmol/L REF.
4.7–5.0 mmol/L 1.08 (0.69–1.69) 0.754 1.07 (0.68–1.69) 0.773
5.1–5.5 mmol/L 2.22 (1.38–3.57) <0.001 2.31 (1.43–3.75) <0.001
5.6–7.8 mmol/L 2.82 (1.39–5.71) 0.004 2.54 (1.22–5.29) 0.012
 (Continued)
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CI, 1.26–2.57; P=0.001; 5.6–7.8 mmol/L: HR, 2.61; 95% 
CI, 1.56–4.35; P<0.001).
Seventh, by retaining the last available plasma potassium 
measurement within 6 to 100 days of the first potassium 
measurement (instead of the first available measurement) 
we observed similar results with the main analysis.
Eighth, multivariable analyses adjusted for 
potassium concentrations obtained at the first 
measurement showed similar results to the main 
analysis: Potassium levels outside the interval 4.6 to 
5.5 mmol/L after a recent episode of hyperkalemia 
were associated with increased short-term mortality 
risk.
Ninth, analyses including time between first and 
second potassium draw as a covariate showed similar 
results to the main analysis.
Univariable Analysis Multivariable Analysis
HR 95% CI P Value HR 95% CI P Value
6. Cardiovascular death (all-cause mortality as competing risk, N=7620)
2.2–2.9 mmol/L 10.02 (5.07–19.80) <0.001 6.86 (3.40–13.85) <0.001
3.0–3.4 mmol/L 5.01 (3.24–7.75) <0.001 3.21 (2.05–5.04) <0.001
3.5–3.7 mmol/L 2.44 (1.54–3.86) <0.001 1.85 (1.15–2.96) 0.010
3.8–4.0 mmol/L 1.80 (1.25–2.58) 0.001 1.56 (1.09–2.25) 0.022
4.1–4.6 mmol/L REF.
4.7–5.0 mmol/L 0.99 (0.71–1.38) 0.953 0.97 (0.70–1.37) 0.880
5.1–5.5 mmol/L 2.11 (1.48–3.00) <0.001 1.80 (1.26–2.57) 0.001
5.6–7.8 mmol/L 2.70 (1.63–4.45) <0.001 2.61 (1.56–4.35) <0.001
7. Last potassium measurement available within 6–100 d from the first potassium measurement (N=7620)
2.2–2.9 mmol/L 10.54 (6.02–18.47) <0.001 8.00 (4.53–14.13) <0.001
3.0–3.4 mmol/L 4.44 (3.17–6.23) <0.001 3.29 (2.33–4.64) <0.001
3.5–3.7 mmol/L 3.17 (2.40–4.18) <0.001 2.55 (1.92–3.38) <0.001
3.8–4.0 mmol/L 1.43 (1.09–1.87) 0.011 1.28 (0.97–1.68) 0.082
4.1–4.6 mmol/L REF.
4.7–5.0 mmol/L 1.18 (0.94–1.49) 0.164 1.16 (0.92–1.47) 0.213
5.1–5.5 mmol/L 1.93 (1.45–2.55) <0.001 1.59 (1.19–2.13) 0.002
5.6–7.8 mmol/L 7.04 (5.22–9.51) <0.001 3.73 (2.70–5.15) <0.001
8. Multivariable analyses adjusted for potassium concentrations obtained at the first measurement as well
2.2–2.9 mmol/L 4.63 (2.66–8.06) <0.001
3.0–3.4 mmol/L 2.39 (1.69–3.40) <0.001
3.5–3.7 mmol/L 1.74 (1.26–2.39) <0.001
3.8–4.0 mmol/L 1.38 (1.06–1.78) 0.013
4.1–4.6 mmol/L REF.
4.7–5.0 mmol/L 0.90 (0.72–1.14) 0.391
5.1–5.5 mmol/L 1.27 (0.97–1.66) 0.080
5.6–7.8 mmol/L 2.17 (1.53–3.07) <0.001
9. Multivariable analysis adjusted for time between first and second potassium measurement as well
2.2–2.9 mmol/L 3.74 (2.15–6.51) <0.001
3.0–3.4 mmol/L 1.95 (1.38–2.76) <0.001
3.5–3.7 mmol/L 1.55 (1.13–2.14) 0.007
3.8–4.0 mmol/L 1.24 (0.96–1.61) 0.103
4.1–4.6 mmol/L REF.
4.7–5.0 mmol/L 0.92 (0.73–1.16) 0.502
5.1–5.5 mmol/L 1.32 (1.01–1.73) 0.043
5.6–7.8 mmol/L 2.25 (1.60–3.18) <0.001
Adjusted for age, sex, plasma sodium, renal insufficiency (÷1), malignancy (÷2), heart failure (÷3), chronic liver disease, chronic obstructive pulmonary 
disease, diabetes mellitus, stroke, atrial flutter/fibrillation, ischemic heart disease (÷4), inflammatory bowel disease, antihypertensive therapy, corticosteroids, 
antimicrobials, non-steroidal anti-inflammatory drugs, xanthines, laxatives, digoxin and potassium supplement. HR indicates hazard ratio; and ICD-10, 
International Classification of Diseases, Tenth Revision.
Table 2. Continued
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DISCUSSION
This Danish register-based cohort study investigated 
the 90-day mortality among 7620 patients with hy-
pertension and hyperkalemia in relation to the sub-
sequent plasma potassium measurement. The major 
findings were: (1) More than one-third of the patients 
with initial hyperkalemia persisted with hyperkalemia 
at a subsequent measurement; (2) potassium concen-
trations >5.5 mmol/L were associated with increased 
all-cause and cardiovascular mortality; (3) decrease in 
potassium to levels <4.1 mmol/L in patients with initial 
hyperkalemia was associated with increased mortal-
ity risk (all-cause and cardiovascular) compared with 
the reference (4.1–4.6  mmol/L); (4) aiming for potas-
sium concentrations between 4.1 and 5.5  mmol/L, 
after an episode of hyperkalemia, was associated with 
increased survival.
Numerous studies have previously shown the im-
portance of potassium on mortality in different pop-
ulations with or without cardiovascular disease.3,13–17 
However, no prior studies have examined the risk of 
mortality in patients who persisted with hyperkalemia 
or who had hypokalemia at the second measurement 
compared with patients with normal plasma potassium 
concentrations.
We observed a significantly increased mortality risk 
among patients who, following an episode of hyper-
kalemia, had their potassium downregulated to levels 
<4.1  mmol/L within 6 to 100  days. This finding was 
expected considering our previous findings,3 where 
we observed an apparent optimal potassium range 
within 4.1 to 4.7  mmol/L in a similar population. We 
also observed significant associations with presumed 
cardiovascular death. Potassium concentrations <4.1 
and >5.5 mmol/L are associated with both all-cause 
and cardiovascular mortality, which might suggest that 
potassium has 2 roles: risk factor and risk marker. In 
other words, potassium in itself could be responsible 
for mortality, and potassium abnormalities could iden-
tify sicker patients with increased risk of mortality or 
patients physiologically or genetically “unable” to main-
tain potassium homeostasis when having concurrent 
heart disease.
A retrospective register-based study, using records 
of 114 977 emergency department patients hospital-
ized from October 2016 to October 2017, showed that 
potassium normalization within the first 8 hours after 
hyperkalemia (≥5.5  mmol/L) at admission was asso-
ciated with 50% mortality reduction.18 Distribution 
of comorbidities was not described by the authors; 
therefore, we cannot compare the burden of cardio-
vascular diseases. However, the findings of Singer 
et al18 are a wake-up call. In our study, we also ob-
served that plasma potassium >5.5 mmol/L (after an 
episode of hyperkalemia) was associated with higher 
mortality compared with concentrations between 4.1 
and 4.6 mmol/L.
McMahon et al19 examined the association be-
tween the highest potassium concentration on the 
admission day and 30-, 90- and 365-day mortality 
in >39 000 intensive care unit–treated patients. The 
authors found significantly higher mortality in pa-
tients with potassium levels >4.5 mmol/L. Moreover, 
the study showed a better prognosis in patients who 
had a decline in potassium concentration >1 mmol/L 
within 48 hours following critical care initiation. Our 
study suggested that lowering potassium levels in pa-
tients who originally had concentrations >4.6 mmol/L 
was beneficial. However, the survival benefit was lost 
when potassium was corrected to levels <4.1 mmol/L. 
Another study by Khanagavi et al20 including hospi-
talized patients with potassium levels >5.1  mmol/L 
reported that the duration of hyperkalemia was as-
sociated with increased risk of death. Unfortunately, 
we do not have information about the duration of 
hyperkalemia. However, according to good clinical 
practice, most clinicians in Denmark do not initiate 
or change antihypertensive treatment unless blood 
tests are available within a short period of time. Data 
from the studies mentioned above suggested that 
not only the absolute value of potassium was import-
ant in relation to mortality, but also duration of hy-
perkalemia, the severity of disease, and velocity and 
magnitude of potassium correction.
We noted that kidney insufficiency, age, history of 
malignancy, stroke, chronic obstructive pulmonary 
disease, atrial fibrillation, and chronic liver disease and 
hospitalization at the time of potassium measurement 
were significant predictors of mortality. An et al21 found 
similar predictors of mortality in patients with severe 
hyperkalemia requiring hospitalization.
Limitations
Because of the observational design, we cannot ex-
clude residual confounding such as vomiting, diarrhea, 
or diet, as this information was not available.
At the first potassium measurement, all patients 
had a plasma potassium level >4.6 mmol/L, and it is 
expected that treatment for potassium normalization 
is initiated immediately afterwards, at least in patients 
with concentrations >5.0 mmol/L. However, it was not 
possible in this register-based study to explore the 
effect of any potential effectuated treatment or drug 
adjustment. The Danish National Prescription Registry 
registers filled prescriptions; thus, a decrease or an in-
crease in dosage could not be traced. In addition, the 
majority of the patients were hospitalized at the time 
of potassium measurement, and any treatment under 
hospitalization is not registered in the Danish National 
Prescription Registry.
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There is a possibility that potassium normalization 
(at the second potassium measurement) can be ex-
plained by regression toward the mean and not by 
any active pharmacological or nonpharmacological 
intervention. Regression toward the mean implies 
that some of the extreme values at the first mea-
surements should be results of random error and 
therefore be closer to the mean at the second mea-
surement. This would lead to more people having 
normalized their potassium in addition to those who 
had it corrected. This would result in a biased con-
clusion/observation of the group that had potassium 
corrected, but not for the group in which dyskalemia 
persisted.
We cannot exclude the possibility of hemolyzed 
blood specimens. However, in case of significant 
hemolysis with high hemolytic index, laboratories 
frequently reject plasma samples submitted for potas-
sium measurement and mark these with no values.
Information on comorbidities and risk factors from 
the primary sector was not available. Therefore, pa-
tients who were not prescribed any of the medications 
of interest or were not registered an ICD code from 
the secondary sector might have been misclassifies as 
“healthy.” Patients with complications related to hyper-
tension are more likely to be referred to the second-
ary sector and therefore have a higher probability for 
being diagnosed with other conditions (compared with 
patients with uncomplicated hypertension), leading to 
an ascertainment/surveillance bias and nondifferential 
misclassification bias. To reduce this bias, we defined 
hypertension as use of at least 2 antihypertensive 
drugs in 2 concomitant quarters. Whether hyperten-
sion was resistant, controlled, or uncontrolled was un-
known, and data about ejection fraction and etiology of 
heart failure were not available.
Because of multiple comparisons, we cannot ex-
clude the possibility of inflated type I error. In this study 
we have 21 comparisons, and the critical P value of 
<0.05 in a worst-case scenario should be ≤0.002, 
correcting for the comparisons. This correction holds 
for all comparisons except potassium group 3.8 to 
4.0 mmol/L, where the P value was 0.01.
Because of the great burden of comorbidities and 
administration of combination antihypertensive ther-
apy, the results of this paper are not generalizable to 
the entire population with high blood pressure.
Finally, our results can be interpreted only as asso-
ciations, and no causal relations can be drawn from 
this study.
CONCLUSIONS
Overcorrection of hyperkalemia to levels <4.1 mmol/L 
was frequent and associated with increased all-cause 
and cardiovascular mortality. Potassium concentra-
tions >5.5 mmol/L were also associated with increased 
all-cause and cardiovascular mortality.
PERSPECTIVES
Although we may not be able to report the mechanism 
through which potassium was lowered, our results em-
phasized the importance of potassium normalization 
after an episode of hyperkalemia and nonradical cor-
rection of hyperkalemia in patients with hypertension 
treated with combination antihypertensive therapy.
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Table S1. List of antihypertensive drugs and corresponding ATC codes used to define 
hypertension. 
ATC codes Name of drug 
C02A Antiadrenergic agents, centrally acting 
C02B Antiadrenergic agents, ganglion blocking 
C02C Antiadrenergic agents, peripherally acting 
C02DA Thiazide-derivatives 
C02DB Hydrazynophthalazin-derivatives 
C02DD Nitroferricyanide-derivatives 
C02DG Guanidin-derivatives 
C02L Antihypertensives and diuretics in combination 
C03AA Thiazides 
C03AB Thiazides and potassium in combination 
C03BA Sulfonamides 
C03BB Sulfonamides and potassium in combination 
C03C Loop diuretics 
C03DA Aldosteron antagonists 
C03DB Other potassium sparing agents 
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C03EA Low-ceiling diuretics and potassium sparing 
agents 
C03EB High-ceiling diuretics and potassium sparing 
agents 
C03X Other diuretics 
C07A Beta-blockers 
C07B Beta-blockers and thiazides 
C07C Beta-blockers and other diuretics 
C07D Beta-blockers, thiazides and other diuretics 
C07FB Beta-blockers and calcium antagonists 
C07FX Beta-blockers and other combinations 
C08C Selective calcium antagonists primarily with 
vascular effect 
C08D Selective calcium antagonists with direct 
cardiac effect  
C08E Non-selective calcium antagonists 
C08G Calcium antagonists and diuretics 
C09AA Angiotensin converting enzyme inhibitors 
C09BA Angiotensin converting enzyme inhibitors and 
diuretics 
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C09BB Angiotensin converting enzyme inhibitors and 
calcium antagonists 
C09CA Angiotensin II antagonists  
C09DA Angiotensin II antagonists and diuretics 
C09DB Angiotensin II antagonists and calcium 
antagonists 
C09XA Renin-inhibitors 
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Table S2. Definitions of comorbidities, procedures and concomitant medications based on 
different ICD-10, Nordic Classification of Surgical Procedures (NCSP), and ATC codes 
identified prior to index date. 
 
 ICD-10 
codes 
Time 
prior to 
index date 
NCSP 
codes 
Time 
prior to 
index date 
ATC 
codes 
Time 
prior to 
index date 
Comorbidities and procedures 
Ischemic heart 
disease including 
myocardial 
infarction1 
I20-25 5 years KFNG, 
KFNA-E 
5 years − − 
Atrial flutter or 
fibrillation 
I48 5 years − − − − 
Chronic obstructive 
pulmonary disease 
J40-44 5 years − − − − 
Chronic liver 
disease 
B18, 
C22, 
K71-77 
5 years − − − − 
Syndrome of 
inappropriate 
antidiuretic 
hormone secretion 
E22.2 5 years − − − − 
Diabetes insipidus E23.2, 
N25.1 
5 years − − − − 
Addison disease E27.1 5 years − − − − 
Primary 
hyperaldosteronism 
E26.0 5 years − − − − 
Diabetes E10-14 5 years − − − − 
Cancer C00-99 5 years − − − − 
Hypertension DI11-15 5 years − − − − 
Heart failure I110, 
I130, 
5 years − − − − 
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I132, 
I42, I50, 
J81 
Stroke DI61, 
DI62, 
DI63, 
DI64, 
DG458-
459, 
DG433-
438 
5 years − − − − 
Inflammatory 
bowel disease (IBD) 
DK50-51 5 years − − − − 
Concomitant medications 
Potassium 
supplements 
− − − − A12B 
C03AB 
C03BB 
C03CB 
90 days 
Loop diuretics − − − − C03C 90 days 
Non-steroidal anti-
inflammatory drugs 
− − − −  M01A 180 days 
Antimicrobials − − − − J01CF06, 
J01CA01, 
J01CE, 
J01G, 
J02AA01, 
J05AD01, 
J01CF05 
30 days 
β2-agonists − − − − R03AC02, 
C01CA2, 
C01CA24, 
R03AC13 
C01CA02, 
R03AB02 
R03CB01, 
90 days 
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R01BA02, 
R03AC03, 
R03AC12 
 
 
Mineralo- and 
glucocorticoids 
− − − − A01AC03, 
A07EA02, 
C05AA01, 
D07AA02, 
H02AB09, 
S01BA02, 
S02BA01, 
H02AA02, 
A07EA03, 
H02AB07 
 
 
90 days 
Laxatives − − − − V03AE01, 
A06AB04,  
A06AG10 
 
 
30 days 
Xantines − − − − R03DA04, 
N06BC01 
 
30 days 
Macrolides − − − − J01FA 30 days 
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Table S3. Aikaike Information Criterion and area under the ROC curve for the main model and sensitivity analyses. 
  
Univariable 
analysis 
Multivariable 
analysis  
AIC AUC AIC AUC 
Main model 11156 0.60 10605 0.74 
Sensitivity analyses 
    
1. Patients with normal kidney function (N= 6505) 8435 0.61 7992 0.73 
2. Patients without past history with malignancy (N= 6383) 6949 0.60 6636 0.73 
3. Patients without past history with heart failure or loop diuretic prescriptions (N= 
3149) 
2486 0.56 2287 0.79 
4. Patients without past history with ischemic heart disease (N= 5121) 7949 0.60 7567 0.77 
5. Patients with and ICD-10 hypertension diagnosis (N= 2410 ) 2639 0.61 2505 0.79 
6. Cardiovascular death (all cause mortality as competing risk, N= 7620) 5631 0.88 5354 0.78 
7. Last potassium measurement available within 7-100 days from the first potassium 
measurement (N= 7620) 
10840 0.60 10137 0.75 
8. Main model adjusted for the first potassium measurement as well 11156 0.60 10606 0.74 
9. Main model adjusted for the time from first to second potassium measurement as 
well 
11156 0.60 10500 0.76 
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Table S4. Hospitalization diagnoses at the time of second potassium measurement. 
 
 
Primary and secondary diagnoses Frequency 
DA00-DB99 Certain infectious and parasitic diseases 60 
 
DC00-DD48 Neoplasm 61 
 
DD50-DD89 Diseases of the blood and blood-forming organs and certain disorders involving the immune 
mechanism 
50 
 
DE00-DE90 Endocrine, nutritional and metabolic disorders 118 
 
DG00-DG99 Diseases of the nervous system 43 
 
DI00-DI99 Diseases of the circulatory system 558 
 
Heart disease 
 
449 
DJ00-DJ99 Diseases of the respiratory system 494 
 
DK00-DK93 Diseases of the digestive system 301 
 
DL00-DL99 Diseases of the skin and subcutaneous tissue 47 
 
DM00-DM99 Diseases of the muculoskeletal system and connective tissue 154 
 
DN00-DN99 Diseases of the genitourinary system 365 
 
Glomerular diseases, Renal tubulo-interstitial diseases or Renal failure 
 
227 
DR00-DR99 Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified 694 
 
DS00-DT98 Injury, poisoning and certain other consequences of external causes 301 
 
DZ00-DZ99 Factors influencing health status and contact with health services 1277 
 
Others 106 
 
   
Total: 4629 
 
Others include: 
  
DF00-DF99 Mental and behavioural disorders 
  
DH00-DH59 Diseases of the eye and adnexa 
  
DQ00-DQ99 Congenital malformations, deformations and chromosomal abnormalities 
  
DV01-DY98 External causes of morbidity and mortality 
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Table S5. Distribution of the first potassium measurement and potassium draws within 1-5 days from the first potassium 
measurement (stratified by the second potassium measurement groups)  
   
2.2-2.9 
mmol/L 
(n=29) 
3.0-3.4 
mmol/L 
(n=130) 
3.5-3.7 
mmol/L 
(n=164) 
3.8-4.0 
mmol/L 
(n=336) 
4.1-4.6 
mmol/L 
(n=898) 
4.7-5.0 
mmol/L 
(n=361) 
5.1-5.5 
mmol/L 
(n=181) 
5.6-7.8 
mmol/L 
(n=62) 
Total (n=2161) p-
value 
First potassium measurement median(range) 4.9(4.7, 
6.6) 
4.8(4.7, 
8.9) 
4.9(4.7, 
7.5) 
4.9(4.7, 
8.2) 
4.9(4.7, 
9.1) 
4.9(4.7, 
8.0) 
5(4.7, 
7.7) 
5.1(4.7, 
7.3) 
4.9(4.7, 9.1) <0.001 
First potassium measurement 
(groups) 
4.7-5.5 
mmol/L 
22 (75.9) 112 (86.2) 150 (91.5) 308 (91.7) 818 (91.1) 323 (89.5) 156 
(86.2) 
48 (77.4) 1,937 (89.6) 
 
 
>5.5 mmol/L 7 (24.1) 18 (13.8) 14 (8.5) 28 (8.3) 80 (8.9) 38 (10.5) 25 (13.8) 14 (22.6) 224 (10.4) <0.001 
Average of potassium drawn 
between 1-5 days from the first 
potassium measurement 
mean (sd) 3.8 (0.6) 4 (0.5) 4.1 (0.5) 4.3 (0.4) 4.4 (0.4) 4.6 (0.4) 4.8 (0.5) 4.9 (0.6) 4.4 (0.5) <0.001 
Death-90 days 
 
14 (48.3) 32 (24.6) 35 (21.3) 52 (15.5) 125 (13.9) 53 (14.7) 43 (23.8) 20 (32.3) 374 (17.3) <0.001 
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Table S6. Causes of death. 
 
Causes of death Frequency 
Cardiovascular 318 
Certain infectious and parasitic disease 14 
Neoplasm 116 
Mental and behavioural disorders 8 
Diseases of the nervous system 4 
Diseases of the respiratory system 35 
Diseases of the digestive system 46 
Diseases of the genitourinary system 6 
Others 25 
missing  61 
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Table S7. Demographics by survival status. 
   
Alive (n=6998) Deceased 
(n=622) 
Total (n=7620) p-value 
Second potassium measurement median(range) 4.5(2.3, 7.8) 4.4(2.2, 7.6) 4.5(2.2, 7.8) 0.001 
First potassium measurement median(range) 4.8(4.7, 9.1) 4.9(4.7, 7.4) 4.8(4.7, 9.1) < 
0.0001 
Age median(range) 69.8( 18.2, 102.3) 75.1( 19.5, 101.8) 70.3( 18.2, 
102.3) 
< 
0.0001 
Sex Female 2,769 (39.6) 292 (46.9) 3,061 (40.2) 
 
 
Male 4229 (60.4) 330 (53.1) 4,559 (59.8) 0.0004 
Renal insufficiency (second 
measuremt) 
 
973 (13.9) 142 (22.8) 1,115 (14.6) < 
0.0001 
Serum sodium (second 
measurement) 
median(range) 139(108, 166) 135(112, 169) 139(108, 169) < 
0.0001 
Renal insufficiency (first 
measuremt) 
 
924 (14.1) 123 (20.5) 1,047 (14.6) < 
0.0001  
missing 
  
446 
 
Hospitalization at the time of 
first potassium measurement 
 
1992 (28.6) 400 (64.3) 2,392 (31.5) < 
0.0001 
Hospitalization at the time of 
second potassium measurement 
 
5876 (84.0) 576 (92.6) 6,452 (84.7) < 
0.0001 
Malignancy 
 
1012 (14.5) 225 (36.2) 1,237 (16.2) < 
0.0001 
Chronic obstructive pulmonary 
disease 
 
938 (13.4) 144 (23.2) 1,082 (14.2) < 
0.0001 
Atrial fibrillation/Atrial flutter 
 
1569 (22.4) 165 (26.5) 1,734 (22.8) 0.023 
Chronic kidney disease 
 
881 (12.6) 72 (11.6) 953 (12.5) 0.501 
Chronic liver disease 
 
276 (3.9) 78 (12.5) 354 (4.6) < 
0.0001 
Hypertension (ICD-10) 
 
2243 (32.1) 167 (26.8) 2,410 (31.6) 0.01 
Ischemic heart disease 
 
2342 (33.5) 157 (25.2) 2,499 (32.8) < 
0.0001 
Diabetes 
 
1798 (25.7) 117 (18.8) 1,915 (25.1) 0.0002 
Heart failure 
 
2315 (33.1) 214 (34.4) 2,529 (33.2) 0.532 
Stroke 
 
653 (9.3) 88 (14.1) 741 (9.7) 0.0001 
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Figure S1. Population flowchart. 
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Figure S2. Distribution of the first potassium measurement (1, n= 7620), average potassium 
measurements drawn within 1-5 days from the first potassium measurement (2, n= 2161) 
and distribution of the second potassium measurement (3, n= 7620). 
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